RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 1/Phase 2

Registered title, quoted from ClinicalTrials.gov

Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients

An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07235176, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Local recurrent or metastatic advanced ER+/HER2- breast cancer confirmed by histopathology or cytopathology;

    Inclusion criterion 5

  3. Subjects have not recovered from adverse events (AEs) caused by previous anti-tumor treatment to ≤ grade 1.

    Exclusion criterion 4

  4. ECOG score: 0-1

    Inclusion criterion 3

  5. Baseline presence of at least one measurable lesion according to the RECIST v1.1;

    Inclusion criterion 7

  6. Subjects have other active malignant tumors within 3 years before the first use of the investigational drug.

    Exclusion criterion 6

  7. Female subjects with fertility and male subjects must agree to use highly effective contraception during the study treatment period and within 180 days after the last medication;

    Inclusion criterion 9

    Female subjects with fertility must have a negative serum HCG test within 7 days before the first medication in the study, and must be in non lactation.

    Inclusion criterion 10

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07235176, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Volunteer to participate in this study, sign an informed consent form and have good compliance;
  • Age ≥ 18 years old, Male or female
  • ECOG score: 0-1
  • Expected survival ≥ 12 weeks
  • Local recurrent or metastatic advanced ER+/HER2- breast cancer confirmed by histopathology or cytopathology;
  • Failed to at least one therapy line of endocrine therapy ;
  • Baseline presence of at least one measurable lesion according to the RECIST v1.1;
  • The functional level of important organs is basically normal, meeting the requirements of the scheme;
  • Female subjects with fertility and male subjects must agree to use highly effective contraception during the study treatment period and within 180 days after the last medication;
  • Female subjects with fertility must have a negative serum HCG test within 7 days before the first medication in the study, and must be in non lactation.
  • Volunteer to participate in this clinical trial, willing and able to follow the procedures related to clinical visits and research, understand the research procedures, and have signed informed consent.

Exclusion Criteria:

  • Subjects have received live or attenuated live vaccines within 4 weeks before the first use of the investigational drug.
  • Subjects have undergone major organ surgery within 4 weeks before the first use of the investigational drug.
  • Subjects require long-term or high-dose use of non-steroidal drugs.
  • Subjects have not recovered from adverse events (AEs) caused by previous anti-tumor treatment to ≤ grade 1.
  • Subjects have a known or suspected severe allergy to the investigational drug or any of its components.
  • Subjects have other active malignant tumors within 3 years before the first use of the investigational drug.
  • Subjects have brain metastases and/or carcinomatous meningitis or leptomeningeal disease.
  • Subjects have active tuberculosis, radiation pneumonitis, drug-induced pneumonitis, pulmonary fibrosis, or other diseases, symptoms, or signs of severe lung function impairment.
  • Subjects are unable to swallow tablets or had gastrointestinal abnormalities that the investigator assessed as potentially affecting drug absorption.
  • Subjects have a history of severe cardiovascular or cerebrovascular disease within 6 months before the first use of the investigational drug.
  • Subjects have a hypertension medial history that blood is not well controlled despite treatment with multiple antihypertension drugs.

Quoted from ClinicalTrials.gov, NCT07235176, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07235176, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07235176